|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
189,490,000 |
Market
Cap: |
1.51(B) |
Last
Volume: |
1,754,233 |
Avg
Vol: |
4,315,920 |
52
Week Range: |
$4.13 - $8.69 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1115 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
183,601 |
183,601 |
183,601 |
Total Buy Value |
$0 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
Total People Bought |
0 |
10 |
10 |
10 |
Total Buy Transactions |
0 |
10 |
10 |
10 |
Total Shares Sold |
0 |
11,387 |
11,387 |
506,586 |
Total Sell Value |
$0 |
$69,059 |
$69,059 |
$6,068,300 |
Total People Sold |
0 |
2 |
2 |
10 |
Total Sell Transactions |
0 |
2 |
2 |
16 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-05 |
4 |
S |
$10.59 |
$396,066 |
D/D |
(37,400) |
160,802 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-04 |
4 |
S |
$10.50 |
$110,198 |
D/D |
(10,495) |
198,202 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-03-01 |
4 |
D |
$10.20 |
$17,738 |
D/D |
(1,739) |
95,123 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-01 |
4 |
D |
$10.20 |
$16,667 |
D/D |
(1,634) |
208,697 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-03-01 |
4 |
D |
$10.20 |
$4,743 |
D/D |
(465) |
165,144 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2015-03-01 |
4 |
D |
$10.20 |
$11,424 |
D/D |
(1,120) |
71,876 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-03-01 |
4 |
D |
$10.20 |
$52,204 |
D/D |
(5,118) |
650,869 |
|
- |
|
Cohen Fred E |
Director |
|
2015-02-27 |
4 |
A |
$10.20 |
$8,741 |
D/D |
857 |
102,314 |
|
- |
|
Hutson Nancy J |
Director |
|
2015-02-20 |
4 |
B |
$10.27 |
$102,700 |
D/D |
10,000 |
15,891 |
2.39 |
- |
|
Powell Lynne |
Senior VP - CCO |
|
2015-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2015-01-20 |
4 |
D |
$11.17 |
$24,686 |
D/D |
(2,210) |
72,370 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-01-20 |
4 |
D |
$11.17 |
$56,677 |
D/D |
(5,074) |
95,609 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-01-20 |
4 |
D |
$11.17 |
$48,724 |
D/D |
(4,362) |
210,331 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-01-20 |
4 |
D |
$11.17 |
$49,997 |
D/D |
(4,476) |
164,913 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-01-20 |
4 |
D |
$11.17 |
$118,491 |
D/D |
(10,608) |
654,280 |
|
- |
|
Cohen Fred E |
Director |
|
2015-01-08 |
4 |
OE |
$1.29 |
$129,000 |
D/D |
100,000 |
101,457 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-01-01 |
4 |
D |
$12.16 |
$29,208 |
D/D |
(2,402) |
214,693 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,900 |
217,095 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-01-01 |
4 |
D |
$12.16 |
$33,258 |
D/D |
(2,735) |
100,683 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,900 |
103,418 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-01-01 |
4 |
D |
$12.16 |
$29,828 |
D/D |
(2,453) |
169,389 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,900 |
171,842 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2015-01-01 |
4 |
D |
$12.16 |
$29,828 |
D/D |
(2,453) |
74,580 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2015-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
77,033 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-01-01 |
4 |
D |
$12.16 |
$68,728 |
D/D |
(5,652) |
664,888 |
|
- |
|
755 Records found
|
|
Page 19 of 31 |
|
|